An Open-Label, Pilot Study To Investigate Feasibility and Safety Of Using Bortezomib, Rituximab, Ifosfamide, Carboplatin, Etoposide As Salvage Regime In Previously Treated Patients With Diffuse Large B-Cell Lymphoma.

Trial Profile

An Open-Label, Pilot Study To Investigate Feasibility and Safety Of Using Bortezomib, Rituximab, Ifosfamide, Carboplatin, Etoposide As Salvage Regime In Previously Treated Patients With Diffuse Large B-Cell Lymphoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 May 2017

At a glance

  • Drugs Bortezomib (Primary) ; Carboplatin; Etoposide; Granulocyte colony-stimulating factors; Ifosfamide; Mesna; Rituximab
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 25 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 14 Apr 2016 Planned End Date changed from 1 Sep 2015 to 1 Sep 2016.
    • 14 Apr 2016 Planned primary completion date changed from 1 Sep 2015 to 1 Sep 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top